Acute tryptophan depletion and Lewy body dementias

Mace, Janet L.; Porter, Richard; Dalrymple‐Alford, John C.; Collins, Chris; Anderson, Tim

doi:10.1017/s1041610216000284

Cited by 4 publications

(4 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies show that 5-HT receptor-antagonists have antipsychotic and antidepressant properties, whereas agonist ligands possess cognition-enhancing and hallucinogenic properties. In addition, the effects of a rapid reduction in 5-HT function have shown a reduction in cognitive status in dementia with Lewy bodies (54). Consequently, antidepressants may be useful in treating depression in PD (55).…”

Section: Serotonin Stimulates Gpcrs and Pi3k/akt Signaling In Cellsmentioning

confidence: 99%

PI3K/AKT signaling mediated by G protein-coupled receptors is involved in neurodegenerative Parkinson's disease (Review)

Nakano

Matsuda

Ichimura

et al. 2016

International Journal of Molecular Medicine

View full text Add to dashboard Cite

Parkinson's disease (PD) is a common progressive and multifactorial neurodegenerative disease, characterized by the loss of midbrain dopaminergic neurons. Numerous pathological processes including, inflammation, oxidative stress, mitochondrial dysfunction, neurotransmitter imbalance, and apoptosis as well as genetic factors may lead to neuronal degeneration. Motor deficits in PD are due mostly to the progressive loss of nigrostriatal dopaminergic neurons. Neuroprotection of functional neurons is of significance in the treatment of PD. G protein‑coupled receptors (GPCRs) have been implicated in the neuroprotection against PD through the survival of dopaminergic neurons. In addition, phosphatidyl‑inositol‑3‑kinase (PI3K)/AKT signaling has also been demonstrated to be neuroprotective. Knowledge of the mechanisms involved in this cellular protection could be critical for developing treatments to prevent this neurodegenerative disorder. In this review, we highlight the protective roles of the PI3K/AKT signaling pathway in the function of representative serotonin GPCRs. Particular attention is given to the molecular mechanisms of this pathway proposed to explain the favorable effects of food ingredients against neurodegenerative disease.

show abstract

Section: Serotonin Stimulates Gpcrs and Pi3k/akt Signaling In Cellsmentioning

confidence: 99%

PI3K/AKT signaling mediated by G protein-coupled receptors is involved in neurodegenerative Parkinson's disease (Review)

Nakano

Matsuda

Ichimura

et al. 2016

International Journal of Molecular Medicine

View full text Add to dashboard Cite

show abstract

“…No PubMed publications were protocol-only. Interventions (from both sources) included donepezil (8),10–17 memantine (8),18–25 rivastigmine (4),26–29 levodopa (4),30–33 nelotanserin (3),34–36 intepirdine (3),37–39 yokukansan (3),40–42 armodafinil (2),43,44 deep brain stimulation (2),45,46 nilotinib (2),47,48 and 1 each of galantamine,49 olanzapine,50 quetiapine,51 ramelton,52 zonisamide,53 tacrine,54 citalopram,55 feru-guard,56 tryptophan depletion,57 treadmill walking,58 cognitive rehabilitation,59 cognitive stimulation,60 and electroconvulsive therapy/transcranial magnetic therapy 61. The comparators were placebo (26),8,14–18,20–22,25,26,32,33,35,36,45,48–51,55,60–65 treatment as usual,59,60 sham stimulation (2),45,46 relaxation therapy (1),59 risperidone,55 and different doses of donepezil (1),17 nelotanserin (1),36 and intepirdine (1) 39.…”

Section: Resultsmentioning

confidence: 99%

“…No PubMed publications were protocol-only. Interventions (from both sources) included donepezil (8), [10][11][12][13][14][15][16][17] memantine (8), [18][19][20][21][22][23][24][25] rivastigmine (4), [26][27][28][29] levodopa (4), [30][31][32][33] nelotanserin (3), [34][35][36] intepirdine (3), [37][38][39] yokukansan (3), [40][41][42] armodafinil (2), 43,44 deep brain stimulation (2), 45,46 nilotinib (2), 47,48 and 1 each of galantamine, 49 olanzapine, 50 quetiapine, 51 ramelton, 52 zonisamide, 53 tacrine, 54 citalopram, 55 feru-guard, 56 tryptophan depletion, 57 treadmill walking,…”

Section: Study Characteristicsmentioning

confidence: 99%

Outcome Measures for Dementia With Lewy Body Clinical Trials

Patel

Irwin

Kaufer

et al. 2021

Alzheimer Disease &Amp; Associated Disorders

View full text Add to dashboard Cite

Background: Dementia with Lewy bodies (DLB) is one of the most common degenerative dementias. Clinical trials for individuals with DLB are increasing. We aimed to identify commonly used outcome measures for trials in DLB. Methods: A pragmatic literature search of PubMed and clinicaltrials.gov identified interventional studies including populations with DLB. Studies were included if they enrolled participants with DLB and met the National Institutes of Health criteria for a clinical trial. Data were collected using standardized forms. Outcome measures were categorized according to core and supportive features of DLB. Results: After de-duplication, 58 trials were identified. The most common cognitive outcome measures were the Mini Mental State Examination (n=24) and Cognitive Drug Research computerized Assessment System (n=5). The Clinician’s Assessment of Fluctuations was the most commonly used measure for fluctuations (n=4). Over half of studies used the Neuropsychiatric Inventory to assess behavioral symptoms (n=31). The Unified Parkinson’s Disease Rating Scale was frequently used for motor assessment (n=23). Conclusions and Relevance: Clinical trial outcomes used in DLB are rarely validated in this population and some lack face validity. There is a need to validate existing scales in DLB and develop DLB-specific outcome measures.

show abstract

“…Clinical studies showed that DLB patients with hallucinations have higher 5-HT turnover in the frontal and temporal cortex compared to AD [334]. Moreover, reduction of global cognitive function in DLB has been attributed to 5-HT deficit [334,335].…”

Section: Serotonergic System In Dementia With Lewy Bodies (Dlb)mentioning

confidence: 99%

Association of Platelet Serotonin Levels in Alzheimer’s Disease with Clinical and Cerebrospinal Fluid Markers

Tajeddinn

Fereshtehnejad

Ahmed

et al. 2016

JAD

View full text Add to dashboard Cite

show abstract

Acute tryptophan depletion and Lewy body dementias

Abstract: This reduction in global cognitive function and the poor tolerability may fit with the hypothesis that people with dementia with Lewy bodies have sensitivity to the effects of reduced serotonin function.

Cited by 4 publications

References 19 publications

PI3K/AKT signaling mediated by G protein-coupled receptors is involved in neurodegenerative Parkinson's disease (Review)

PI3K/AKT signaling mediated by G protein-coupled receptors is involved in neurodegenerative Parkinson's disease (Review)

Outcome Measures for Dementia With Lewy Body Clinical Trials

Association of Platelet Serotonin Levels in Alzheimer’s Disease with Clinical and Cerebrospinal Fluid Markers

Contact Info

Product

Resources

About